Objective: The aim of this study was to evaluate the efficiency and safety profile of fixed combinations of basal insulin and GLP 1 RA in the treatment of patients with type 2 diabetes. Study design: Historical cohort research with historical data. Subjects and methods: All subjects were patients with type 2 diabetes, previously treated with various insulin regimens (BB, BOT, MIX), to whom FRC preparation was implemented from August 2019 to December 2020. Data were collected from available medical records. Results: Out of a total of 145 respondents, 60.7% were women and 39.3% men. There were 35.9% of subjects who were previously treated with the BB insulin regimen, 36.6 % with the BOT regimen, and 27.6 % with the MIX regimen. There were 118 (81.4 %) subjects who were treated with IdegLira and 27 (18.6 %) with IglarLixi. A significant reduction in values of all observed parameters (BW, BMI, HbA1c, FPG, PPG) was found in the previous BB and MIX insulin regimens, but in the case of BOT regimen, just a significant reduction in BMI was observed. When using IdegLira fixed combination, there was a significant reduction in values of all observed parameters except in HbA1c. In the case of IglarLixi preparations, only BMI was significantly reduced. For IglarLixi preparation, an increase in the number of subjects with GIT side effects was observed, while the number of people with hypoglycemia for both drugs was lower after the therapy with FRC preparation. The proportions of changes in OAD after the introduction of the fixed combination do not differ significantly between BB, BOT, and MIX insulin regimens, nor with respect to the use of IDegLir or IglarLixi preparations. Conclusion: The use of fixed combinations of basal insulin and GLP 1 RA in people with type 2 diabetes is more effective than other regimens in achieving glycemic goals, with an acceptable safety profile.